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Edited by Veli-Pekka LehtoAbstract Retention of intron 8 in alternative HER-2 mRNA
generates an inhibitory secreted ligand, Herstatin, with a novel
receptor-binding domain (RBD) encoded by the intron. This
study examines binding interactions with several receptors and
investigates sequence variations in intron 8. The RBD, expressed
as a peptide, binds at nM concentrations to HER-2, the EGFR,
DEGFR, HER-4 and to the IGF-1 receptor, but not to HER-3
nor to the FGF-3 receptor, whereas a rare mutation in the RBD
(Arg to Ile) eliminates receptor binding. The full-length Herst-
atin binds with 3–4-fold higher aﬃnity than its RBD, but with
10-fold lower aﬃnity to the IGF-IR. Sequence conservation in
rhesus monkey but not in rat suggests that intron 8 recently
diverged as a receptor-binding module critical for the function of
Herstatin.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The ErbB receptor family consists of four receptor tyrosine
kinases: EGFR (HER-1, erbB-1), HER-2 (erbB-2), HER-3
(erbB-3) and HER-4 (erbB-4). Aberrant expression of ErbB
receptors by mutational activation, receptor overexpression,
and tumor production of ligands contributes to the develop-
ment and maintenance of a variety of human cancers [1,2].
The ErbB receptors are activated by several ligands con-
sisting of an EGF core domain [3]. The exception is the HER-2
receptor, which is recruited as a preferred dimer partner with
other ligand binding erbB receptors. While the eleven mam-
malian EGF-like ligands are all agonists, the ligand Argos, in
Drosophila, inhibits activation of the EGFR [4,5].
Although the HER-2 receptor does not directly bind EGF-
like ligands, a secreted product of an HER-2 alternative
transcript, Herstatin, binds with nM aﬃnity to the ectodomain
of HER-2. Herstatin consists of a segment of the HER-2 ec-
todomain followed by 79 novel amino acids, encoded by intron
8, which function as a receptor-binding domain (RBD) [6].
Herstatin blocks homomeric and heteromeric ErbB receptor
interactions, inhibits activation of the PI3K/Akt pathway ini-* Corresponding author. Fax: +1-503-494-8393.
E-mail address: clinton@ohsu.edu (G.M. Clinton).
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doi:10.1016/j.febslet.2004.05.027tiated by EGF, TGF-a, and Heregulin, and causes growth
arrest suggesting potential as an anti-cancer agent [6–9].
However, no study has yet addressed the receptor speciﬁcity of
Herstatin. To identify receptor binding targets and to further
assess the signiﬁcance of the novel intron 8-encoded RBD, we
investigated binding to several receptors expressed in trans-
fected cells, examined the consequence of a rare mutation in
intron 8, and compared the sequence in human, rat and rhesus
monkey.2. Materials and methods
2.1. Cell lines, transfections, and Western blots
The 3T3/HER-2 cells were previously described [10]. The 3T3/IGF-
IR cells were from Dr. Charles Roberts, OHSU, Portland, OR. For
transient transfections, 2 lg of empty vector or 2 lg EGFR, HER-2,
HER-3, HER-4, DEGFR, or FGFR-3-myc expression vectors was
added with Lipofectamine (Gibco-BRL) to Cos-7 cells in 6 well plates.
The HER-2 and EGFR expression plasmids were previously described
[7], DEGFR was a gift from Dr. Webster Cavenee (Ludwig Institute,
UCSD, La Jolla, CA), the FGFR-3-myc construct was from Dr. Wil-
liam Horton (Shriners Research Hospital, Portland, OR), and the
HER-4 expression plasmid was a gift of Dr. Nancy Hynes (Friedrich
Miescher-Institute for Biomedical Research, Basel, Switzerland). To
analyze receptors by Western blot analysis, proteins were resolved by
SDS–PAGE and electro-transferred onto nitrocellulose membranes
(BioRad, Hercules, CA). Blots were blocked in 5% milk and incubated
with primary antibody overnight at 4 C. The antibodies included anti-
HER-2 [11], anti-EGFR, anti-HER-3, and anti-HER-4, which were all
rabbit polyclonal antibodies against the receptor C-terminal domains
(Santa Cruz Biotechnology). Antibodies against the b-subunit of IGF-
IR were from Dr. Charles Roberts. After washing, the blots were in-
cubated with secondary antibody conjugated to HRP for 30 min
(BioRad, Hercules, CA). The membranes were developed with Super-
Signal West Dura (Pierce, Rockford, IL) and exposed to X-ray ﬁlm.
2.2. Sequencing of intron 8
Human genomic DNA was obtained from blood samples (supplied
by Dr. David Henner, OHSU) from individuals 18 years or more, after
giving informed consent, with approval by the Institutional Review
Board of OHSU. The samples, assigned random four-digit numbers,
could not be traced to patient identity. The polymerase chain reaction
(PCR), puriﬁcation and sequencing were carried out exactly as previ-
ously described [6]. Electropherograms were individually reviewed to
detect polymorphic alleles. Samples found to contain a polymorphism
were sequenced at least twice to conﬁrm the mutation. Rhesus monkey
DNA, provided by Dr. Scott Wong (ORPC, Portland, OR), was am-
pliﬁed and sequenced in the same manner. Intron 8 in rat genomic
DNA was ampliﬁed by PCR using rat speciﬁc primers: 50-
CTACCTGTCTACGGAAGTGG-30 and 50-TTCCGGGCAGAAAT-
GCCAGG-30. The cycling parameters were: 94 C for 3000; 62 C for
3000; and 72 C for 6000, for 25 cycles.blished by Elsevier B.V. All rights reserved.
Fig. 1. The deduced amino acid sequence encoded by HER-2 (ErbB-2)
intron 8. Alignments are with the most common human intron 8 se-
quence from 214 individuals with non-conserved residues shown.
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Herstatin
The intron 8 cDNA was cloned into the pET30 bacterial expression
vector (Novagen, Madison, WI), expressed in bacteria (BL-21), and
puriﬁed by nickel aﬃnity chromatography as described [6]. For puri-
ﬁcation of insect Herstatin, S2 insect cells, stably transfected with 6
His tagged-Herstatin in the pMT/BiP expression plasmid (Invitrogen,
Carlsbad, CA), were induced with 100 lM cupric sulfate for 16 h.
Herstatin was puriﬁed to 90% purity by Ni–NTA (Qiagen, Valencia,
CA) aﬃnity chromatography as previously described [8].
2.4. Cell binding studies
About 2 106 cells in 6-well plates were incubated with puriﬁed
Herstatin or int8 peptide for 2 h at 4 C in serum-free media. Cells were
washed with phosphate-buﬀered saline (PBS) and extracted in 50 mM
Tris–HCl, pH 7.0, and 1.0% NP-40. Int8 peptide or Herstatin bound to
cells was quantiﬁed using a sandwich Herstatin ELISA as per the
manufacturer’s instructions (Upstate Biotechnology, Lake Placid,
NY). The dissociation constant (Kd) and maximal binding (Bmax) of
Herstatin or the int8 peptide were determined by nonlinear regression
analysis of the plot of pmol of bound versus nM of Herstatin or int8
peptide added. Statistical comparisons between diﬀerent binding
curves were performed by extra sums-of-squares F-test on nonlinear
regression coeﬃcients. All tests were performed (a ¼ 0:05) using
GraphPad Prism 4 software (GraphPad Software, 1994–2003).
2.5. Pull-downs with int8 peptide immobilized on protein S agarose
About 100 ll of a 50% suspension of S-protein agarose (Novagen)
was incubated with or without 100 lg of int8 peptide with an S-protein
tag, at room temperature for 1 h, and then washed twice with 500 ll
PBS. The agarose samples were then incubated at room temperature
for 1 h with 200 lg of transfected Cos-7 cell extract and washed twice
with 500 ll of PBS with 1% NP40. The proteins were eluted from the
resin at 92 C for 2 min in 40 ll of SDS-sample buﬀer and analyzed as
a Western blot.3. Results
3.1. Sequence of human, rhesus monkey, and rat intron 8
Herstatin is generated by retention of HER-2 intron 8,
which encodes the unique C-terminal proline-rich domain of
79 amino acids (Fig. 1). Because of its critical function in re-
ceptor binding [6], we sequenced genomic HER-2 intron 8
from 214 humans, rhesus monkey, and rat. The HER-2 intron
8 deduced amino acid sequence, originally determined from
SKOV3 ovarian cancer cells (AF177761), was found to be the
most common in germ line DNA. In addition, we identiﬁed a
sequence variation in intron 8 (G1112T in AF177761) resulting
in an Arg to Ile substitution at residue 31 in Fig. 1. This mu-
tant allele was found in only one of 215 (<0.5%). The deduced
amino acid sequence of intron 8 from rhesus monkey was 85%
identical to that of humans (Fig. 1) and the nucleotide se-
quence, up to the stop codon, was 93% identical. However,
there was no conservation between rat and human intron 8
(Fig. 1), in contrast to the HER-2 receptor coding sequence,
which is highly conserved in rat neu [12].3.2. Receptor binding of the HER-2 intron 8-encoded peptide
To identify other potential receptor targets of Herstatin, we
examined binding of the intron 8-encoded RBD, expressed as a
bacterial peptide (Int8). Protein S agarose, with or without
immobilized int8 peptide, was incubated with extracts from
Cos-7 cells transiently transfected with several diﬀerent recep-
tors. Following washing steps, the protein bound to the agarose
was analyzed as a Western blot with receptor-speciﬁc antibod-
ies. As previously observed [6,7], EGFR and HER-2 from the
transfected cell extracts bound speciﬁcally to the agarose withint8 peptide (Fig. 2A). In contrast, the int8 peptide with the Arg
to Ile mutation at residue 31 (see Fig. 1) did not pull-down the
HER-2 receptor (Fig. 2B). Fig. 2A also demonstrates that
DEGFR, a tumor variant of the EGFR missing its N-terminal
subdomains I and II [13], speciﬁcally associated with int8 pep-
tide. Another member of the erbB family, HER-4, was also
pulled-down by int8. However, there was no detectable asso-
ciation of HER-3 with int8 peptide agarose despite abundant
expression in the transfected cells (Fig. 2A). We also investi-
gated the possible interaction with the IGF-1 receptor (IGF-
IR), which contains regions of ectodomain sequence homology
with the EGFR [14]. Interestingly, we observed speciﬁc pull-
down of the IGF-IR from transfected cell extracts (Fig. 2A).
The FGFR-3, a receptor tyrosine kinase with Ig-like motifs and
no structural homology with the ErbB family ectodomains, did
not bind to the int8 peptide.
To further examine interaction of the int8 peptide with the
extracellular domain of receptors at the cell surface, an
Herstatin ELISA was used to quantify bound peptide. In
agreement with results obtained by the pull-down assay, the
int8 peptide bound in a speciﬁc and dose-dependent manner to
EGFR, HER-2, HER-4, and DEGFR, but not to HER-3,
FGFR-3, or mock-transfected cells (Fig. 2C). Binding aﬃnities
were further characterized by generating saturation-binding
curves. Int8 peptide bound to HER-2 transfected Cos-7 cells
(Kd ¼ 50 6 nM) and to EGFR transfected Cos-7 cells
(Kd ¼ 78 10 nM) with binding aﬃnities, assessed by com-
parative nonlinear regression analysis, that were not signiﬁ-
cantly diﬀerent (P ¼ 0:40) (Fig. 3A). Further, int8 peptide
bound to the IGF-IR/3T3 cells (Kd ¼ 70 21 nM) and to
HER-2/3T3 cells (Kd ¼ 66 16 nM) with similar aﬃnities
(P ¼ 0:96) (Fig. 3B). In contrast, the mutant int8 peptide with
Arg31Ile did not signiﬁcantly bind to the HER-2 receptor
overexpressing cells at any of the peptide concentrations tested
(Fig. 3C) even though the Herstatin ELISA detected the wild-
type and mutant peptide equally (Fig. 3D). These results
suggested that the int8 peptide bound to EGFR, HER-2, and
IGF-1R with overlapping binding aﬃnities and that the Arg-
Ile mutation inhibited receptor binding without destroying
antibody binding epitopes.
3.3. Receptor binding properties of full-length Herstatin
The full-length Herstatin bound to 3T3/HER-2 cells with a
Kd ¼ 14:7 1:8 nM, which is signiﬁcantly diﬀerent from the
binding aﬃnity of int8 peptide (P < 0:0001) by 3–4-fold. A di-
rect comparison of the binding of Herstatin to 3T3/HER-2 and
3T3/IGF-IR cells revealed that the aﬃnity for the IGF-1R
(Kd  151 nM) was lower (P < 0:0001) by about 10-fold
(Fig. 4A). The dissociation constant ofHerstatin for EGFRwas
similar to that of HER-2, and was unaﬀected by ligand occu-
pation indicated by a Kd ¼ 16:4 3:6 nM versus 16.3 3.6 nM
(respectively) for Cos-7/EGFR treated or not with 10 nM EGF
Fig. 2. Binding of intron 8-encoded peptide to diﬀerent receptors expressed in transfected cells. (A) Extracts from transfected Cos-7 cells were in-
cubated with protein S agarose without or with immobilized wild-type or (B). R31I mutant int8. Associated proteins were analyzed as a Western blot.
(C) Transfected Cos-7 cells were incubated with puriﬁed int8 for 2 h at 4 C in serum-free media, cells were washed, extracted, and analyzed by
Herstatin ELISA.
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ceptors in A431 epidermoid carcinoma cells, which express very
high levels of EGFR and low levels of other ErbB receptors
(Fig. 4C). At saturation, 6.9 0.4 pmol ofHerstatin were boundFig. 3. Saturation binding curves of intron 8 peptide to cells transfected
with HER-2, the EGFR, and the IGF-IR. Diﬀerent amounts of pu-
riﬁed int8 were added to the indicated cells and bound peptide was
quantiﬁed by Herstatin ELISA. Nonlinear regression analysis of
binding data was used to determine the dissociation constants (Kd) and
maximal amount bound. In (A) parental (Cos7) or transiently trans-
fected Cos-7-HER-2 or Cos7-EGFR cells, or in (B) 3T3 cells or stably
transfected HER2-3T3 or IGF-IR-3T3 cells were used. In (C) wild-
type or R31I mutant Int8 peptides were incubated with HER2-3T3
cells. In (D) indicated amounts of wild-type or R31I peptides were
incubated in an Herstatin ELISA.indicating 2 106 binding sites/cell, which matches the num-
ber of EGFR per A431 cell at 2 106 [15]. Comparison of
nonlinear models indicated that a hyperbolic one aﬃnity-site
binding model was the best ﬁt for EGFR-speciﬁc binding of
Herstatin, in the presence and absence of EGF.4. Discussion
Wepresent evidence that intron 8 of theHER-2 gene, retained
in an alternative HER-2 transcript, encodes a receptor binding
domain. We also report that a non-lethal, point mutation of
unknown physiological signiﬁcance, resulting inArg to Ile in the
intron 8-encoded domain, eliminates binding to the HER-2 re-
ceptor. Unaltered interaction of this mutant RBD with two
monoclonal antibodies in an ELISA suggested that global
structure was unaﬀected and that this Arg residue may be di-
rectly involved in receptor binding. While the intron 8 encoded
domain is critical for receptor binding, it does not appear to
aﬀect receptor activity suggesting a requirement for the N-ter-
minal subdomains I and II of Herstatin for receptor inhibition
[6] (Shamieh and Clinton, unpublished observations).
While the intron 8-encoded RBD is critical for the receptor
binding activity of Herstatin, it is not conserved between hu-
mans and rats despite the high degree of sequence identity
between the HER-2 receptor and its rat ortholog, neu. There
are distinct regions in their ectodomains, however, with very
little identity [12]. An additional distinction is that the rat neu
receptor is activated as an oncogene by a single point mutation
in the transmembrane domain, while the human ortholog,
HER-2, is oncogenic without aberrations in the coding se-
Fig. 4. Saturation binding curves of Herstatin to cells expressing dif-
ferent receptors. Herstatin puriﬁed from S2 insect cells was incubated
with: (A) 3T3 cells, HER-2-3T3, or IGF-IR-3T3 cells or in (B) with
parental or transiently transfected Cos-7-EGFR cells serum starved for
24 h and then treated or not for 2 h on ice with 10 nM EGF, or in (C)
A431 epidermoid carcinoma cells.
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functionally equivalent when introduced into HER-2 [17,18].
These collective observations point to diﬀerences in regulation
of the human HER-2 receptor versus its rat ortholog, neu.
Speciﬁc binding of the RBD suggests that the HER-4 re-
ceptor will be a target of Herstatin. Since Herstatin binds to
and blocks the dimerization of the EGFR and HER-2, we
predict that Herstatin will have a similar eﬀect on the struc-
turally similar HER-4. Eﬀects of Herstatin on HER-4 activa-
tion and signaling are currently under investigation. Lack of
Herstatin binding to the other ErbB family member, the HER-
3 receptor, was surprising. HER-3 is unique, however, since it
is kinase deﬁcient and requires an active receptor partner to
signal. The Herstatin binding site may be disguised when
HER-3 is overexpressed without a dimer partner. The binding
of Herstatin to the IGF-IR with nM aﬃnity was unforeseen,
since ligands do not typically cross-react with receptors from
diﬀerent families. Interestingly, the IGF-IR has regions of
ectodomain sequence homology with the EGFR and crosstalk
occurs, most notably, with transactivation of the EGFR by
IGF-1 [19 and references therein]. Our ﬁnding that the binding
aﬃnity of Herstatin, but not its RBD, is signiﬁcantly weaker
for IGF-IR than for HER-2 or the EGFR suggests that sta-
bilizing interactions between the N-terminus of Herstatin and
the receptor ectodomain are lacking. Since IGF-IR does not
have a homologous dimerization loop [14], contacts between
the IGF-IR ectodomain and the dimerization arm in subdo-
main II of Herstatin may be prohibited. The physiologicalsigniﬁcance of Herstatin binding to the IGF-IR remains to be
determined.
In addition to Herstatin, there are several other examples of
alternative forms of ErbB receptors that are created by intron
read-through [20,21]. Creation of truncated receptors fused to
novel C-terminal domains by read-through into introns rep-
resents a novel regulatory mechanism important in the diver-
siﬁcation of receptor signaling. So far, Herstatin is the only
known alternative receptor product that functions as a ligand
and is the only mammalian secreted ligand that inhibits the
EGF receptor family [18,22,23].
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